IDSA supports the FDA’s emergency use authorization for Paxlovid, an oral anti-viral for the treatment of mild-to-moderate COVID-19. This authorization comes at a key moment as the nation and the world face climbing case counts and increased stress on health care systems.
On this World AIDS Day, HIVMA welcomes the release of the Biden-Harris Administration’s 2022 National HIV/AIDS Strategy, which will provide an important road map for ending HIV as an epidemic in the United States.
Discovery of the omicron variant in more than 14 countries to date is the latest evidence that the global COVID-19 pandemic is far from over.
The 14 awarded institutions have created stewardship programs led by infectious diseases-trained physicians and pharmacists that advance science in antimicrobial resistance.
New guidance from the IDSA for treating three of the most common drug-resistant pathogens was published today on the IDSA website.
IDSA supports the FDA and CDC decision to expand eligibility for COVID-19 vaccine boosters to include everyone age 18 and older.
IDSA and HIVMA applaud the bipartisan introduction of the Bolstering Infectious Outbreaks (BIO) Preparedness Workforce Act by Sens. Tammy Baldwin (D-WI) and Susan Collins (R-ME).
IDSA, the nation’s leading infectious diseases professional society, recognizes the distinguished clinicians and scientists from the United States and around the world who were elected this year to be Fellows of IDSA.
IDSA supports COVID-19 vaccine mandates announced by the Occupational Safety and Health Administration for large private employers and the Centers for Medicare and Medicaid Services for employees at Medicare and Medicaid-participating health care facilities.
In recognition of the importance of inclusion, diversity, access and equity as long-term priorities and core values for IDSA, the Society’s Board of Directors recently approved the creation of a permanent IDA&E Committee.
The rise of more transmissible variants of SARS-CoV-2 has spurred growing interest in harnessing information about the genetic sequences of these variants to help treat patients.
To date, 6 million children have been diagnosed with COVID-19. The more than 28 million children who will be eligible to be vaccinated against COVID-19 with this authorization comprise a larger portion of the population than the already eligible 12-17-year-old cohort.